MaxCyte, Inc. (MXCT) earnings
MXCT earnings moved a median of 0.00% by the close. Quarterly and annual MXCT reports and results, each read against the price at its own news timestamp. Back to the MXCT overview →
28 measured MXCT earnings events.
Where these MXCT earnings landedvs 27 measured MXCT earnings reactions
| Middle 50% of MXCT earnings reactions | -4.98% to +8.03% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 27 |
Point-in-time · zero look-ahead
Half of the 27 MXCT earnings events with a measured close landed between -4.98% and +8.03%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance | Press release | +4.92% | +2.46% | |
| Form 10-Q MAXCYTE, INC. For: Jun 30 | SEC filing · Form 10-Q | -1.73% | -5.04% | |
| MaxCyte Reports Second Quarter 2026 Financial Results | Press release | +15.38% | +18.80% | |
| MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 | Press release | +0.35% | -4.93% | |
| Form 10-Q MAXCYTE, INC. For: Mar 31 | SEC filing · Form 10-Q | -1.44% | +4.81% | |
| MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance | Press release | +5.31% | +8.50% | |
| MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 | Press release | -0.24% | +9.73% | |
| Form 10-K MAXCYTE, INC. For: Dec 31 | SEC filing · Form 10-K | +2.66% | +7.79% | |
| MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance | Press release | +3.95% | — | |
| MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance | Press release | -0.34% | +12.84% | |
| MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | Press release | +0.95% | +8.28% | |
| Form 10-Q MAXCYTE, INC. For: Jun 30 | SEC filing · Form 10-Q | -10.05% | -15.88% | |
| MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance | Press release | -10.05% | -15.88% | |
| MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 | Press release | +1.33% | +0.00% | |
| Form 10-Q MAXCYTE, INC. For: Mar 31 | SEC filing · Form 10-Q | -1.03% | -3.09% | |
| MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 | Press release | -3.16% | -7.51% | |
| Form 10-K MAXCYTE, INC. For: Dec 31 | SEC filing · Form 10-K | -10.29% | +2.25% | |
| Form 10-Q MAXCYTE, INC. For: Sep 30 | SEC filing · Form 10-Q | -3.49% | -13.72% | |
| MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance | Press release | -3.49% | -13.72% | |
| MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 | Press release | +0.95% | +4.87% | |
| Form 10-Q MAXCYTE, INC. For: Jun 30 | SEC filing · Form 10-Q | -3.02% | -11.88% | |
| MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 | Press release | -0.48% | -0.96% | |
| Form 10-Q MAXCYTE, INC. For: Mar 31 | SEC filing · Form 10-Q | +10.41% | +17.77% | |
| MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance | Press release | +10.41% | +17.77% | |
| MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 | Press release | +0.73% | -0.24% | |
| Form 10-K MAXCYTE, INC. For: Dec 31 | SEC filing · Form 10-K | +0.86% | +2.72% | |
| Form 10-Q MAXCYTE, INC. For: Sep 30 | SEC filing · Form 10-Q | +1.23% | -0.31% | |
| MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance | Press release | +1.23% | -0.31% |
Keep exploring
More MXCT: analyst actions → · SEC filings → · MXCT overview →